IS6627A - Ónæmisörvandi fádeoxýkirni - Google Patents

Ónæmisörvandi fádeoxýkirni

Info

Publication number: IS6627A
Authority: IS; Iceland
Prior art keywords: deoxyribosepurine; deoxycytosine; deoxyinosine; deoxyguanosine; deoxyadenosine
Prior art date: 2000-06-08

Application number

IS6627A

Other languages

English (en)

Other versions

IS1993B (is

Inventor

Schmidt Walter

Lingnau Karen

Schellack Carola

Egyed Alena

Original Assignee

Intercell Biomedizinische Forschungs- Und Entwicklungs Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-08

Filing date

2002-11-18

Publication date

2002-11-18

2000-06-08 Priority claimed from AT0100000A external-priority patent/AT410173B/de

2002-11-18 Application filed by Intercell Biomedizinische Forschungs- Und Entwicklungs Ag filed Critical Intercell Biomedizinische Forschungs- Und Entwicklungs Ag

2002-11-18 Publication of IS6627A publication Critical patent/IS6627A/is

2005-03-15 Publication of IS1993B publication Critical patent/IS1993B/is

Links

230000003308 immunostimulating effect Effects 0.000 title abstract 2
RPFPNGBGDKGFRI-XLPZGREQSA-N 9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-methyl-3h-purin-6-one Chemical compound C12=NC(C)=NC(O)=C2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 RPFPNGBGDKGFRI-XLPZGREQSA-N 0.000 abstract 2
FERYXNKLCFJNMG-QJPTWQEYSA-N (2r,3s,5r)-2-(hydroxymethyl)-5-[6-(3-methylbut-3-enylamino)purin-9-yl]oxolan-3-ol Chemical compound C1=NC=2C(NCCC(=C)C)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 FERYXNKLCFJNMG-QJPTWQEYSA-N 0.000 abstract 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 abstract 1
COVHWGAKPGOZBI-QJPTWQEYSA-N [(2r,3s,5r)-3-hydroxy-5-[6-(3-methylbut-3-enylamino)purin-9-yl]oxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(NCCC(=C)C)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 COVHWGAKPGOZBI-QJPTWQEYSA-N 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000004712 monophosphates Chemical class 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
229940046166 oligodeoxynucleotide Drugs 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IS6627A 2000-06-08 2002-11-18 Ónæmisörvandi fádeoxýkirni IS1993B (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
AT0100000A AT410173B (de)	2000-06-08	2000-06-08	Antigene zusammensetzung
AT19732000		2000-11-23
PCT/EP2001/006433 WO2001093905A1 (en)	2000-06-08	2001-06-07	Immunostimulatory oligodeoxynucleotides

Publications (2)

Publication Number	Publication Date
IS6627A true IS6627A (is)	2002-11-18
IS1993B IS1993B (is)	2005-03-15

Family

ID=25608484

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS6627A IS1993B (is)	2000-06-08	2002-11-18	Ónæmisörvandi fádeoxýkirni

Country Status (25)

Country	Link
US (3)	US8568742B2 (is)
EP (1)	EP1296713B1 (is)
JP (2)	JP5271471B2 (is)
KR (1)	KR100799788B1 (is)
CN (1)	CN1309418C (is)
AT (1)	ATE249839T1 (is)
AU (2)	AU8181201A (is)
BR (1)	BRPI0111639B8 (is)
CA (1)	CA2411575C (is)
CZ (1)	CZ304195B6 (is)
DE (1)	DE60100814T2 (is)
DK (1)	DK1296713T3 (is)
ES (1)	ES2206424T3 (is)
HU (1)	HU228264B1 (is)
IL (2)	IL152959A0 (is)
IS (1)	IS1993B (is)
MX (1)	MXPA02012010A (is)
NO (1)	NO329492B1 (is)
PL (1)	PL211036B1 (is)
PT (1)	PT1296713E (is)
RU (2)	RU2293573C2 (is)
SI (1)	SI1296713T1 (is)
SK (1)	SK287689B6 (is)
TR (1)	TR200302015T4 (is)
WO (1)	WO2001093905A1 (is)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
EP1322655B1 (en)	2000-01-14	2007-11-14	The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services	Oligodeoxynucleotide and its use to induce an immune response
WO2001093905A1 (en) *	2000-06-08	2001-12-13	Intercell Biomedizinische Forschungs- Und Entwicklungs Ag	Immunostimulatory oligodeoxynucleotides
ES2307568T3 (es) *	2000-12-08	2008-12-01	Coley Pharmaceutical Gmbh	Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
WO2002053185A2 (en) *	2001-01-05	2002-07-11	Intercell Ag	Anti-inflammatory use of polycationic compounds
EP1347775B1 (en)	2001-01-05	2016-11-30	Valneva Austria GmbH	Uses for polycationic compounds as vaccine adjuvants
CA2433967A1 (en) *	2001-01-05	2002-07-11	Intercell Ag	Anti-inflammatory use of polycationic compounds
WO2002053184A2 (en) *	2001-01-05	2002-07-11	Intercell Ag	Uses for polycationic compounds as vaccine adjuvants
AT410798B (de)	2001-01-26	2003-07-25	Cistem Biotechnologies Gmbh	Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
CA2448031A1 (en)	2001-05-21	2002-11-28	Intercell Ag	Method for stabilising of nucleic acids
WO2003035695A2 (en) *	2001-07-26	2003-05-01	Tanox, Inc.	Agents that activate or inhibit toll-like receptor 9
US7666674B2 (en)	2001-07-27	2010-02-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en)	2001-08-14	2003-03-13	The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services	Method for rapid generation of mature dendritic cells
MX339524B (es)	2001-10-11	2016-05-30	Wyeth Corp	Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2452909A1 (en) *	2001-12-07	2003-06-13	Intercell Ag	Immunostimulatory oligodeoxynucleotides
AU2002366710A1 (en)	2001-12-20	2003-07-09	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en)	2001-12-20	2013-06-18	The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8088388B2 (en)	2002-02-14	2012-01-03	United Biomedical, Inc.	Stabilized synthetic immunogen delivery system
CA2388049A1 (en)	2002-05-30	2003-11-30	Immunotech S.A.	Immunostimulatory oligonucleotides and uses thereof
CA2484941A1 (en)	2002-07-24	2004-02-05	Intercell Ag	Antigens encoded by alternative reading frame from pathogenic viruses
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
US7785608B2 (en)	2002-08-30	2010-08-31	Wyeth Holdings Corporation	Immunogenic compositions for the prevention and treatment of meningococcal disease
WO2004024182A2 (en)	2002-09-13	2004-03-25	Intercell Ag	Method for isolating hepatitis c virus peptides
US8263091B2 (en)	2002-09-18	2012-09-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
EP2314603A3 (en)	2002-10-15	2011-05-18	Intercell AG	Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and futher uses thereof
EP1601770B1 (en)	2003-03-04	2009-09-02	Intercell AG	Streptococcus pyogenes antigens
CN100355453C (zh) *	2003-03-24	2007-12-19	英特塞尔股份公司	改进的疫苗
ES2562456T3 (es) *	2003-03-24	2016-03-04	Valneva Austria Gmbh	Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
EP1608756B1 (en)	2003-03-31	2009-11-18	Intercell AG	Staphylococcus epidermidis antigens
EP2333114A1 (en)	2003-04-15	2011-06-15	Intercell AG	S. pneumoniae antigens
EP1620460A2 (en)	2003-05-07	2006-02-01	Intercell AG	Streptococcus agalactiae antigens i + ii
CN102304527A (zh)	2003-05-30	2012-01-04	英特塞尔股份公司	肠球菌抗原
CA2530062A1 (en) *	2003-07-11	2005-01-20	Intercell Ag	Hcv vaccines
JP4817599B2 (ja) *	2003-12-25	2011-11-16	独立行政法人科学技術振興機構	免疫活性増強剤とこれを用いた免疫活性の増強方法
KR100721928B1 (ko) *	2004-11-05	2007-05-28	주식회사 바이오씨에스	ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
EP1931379B1 (en)	2005-10-07	2013-05-29	Health Protection Agency	Proteins with improved solubility and methods for producing and using same
TW200806315A (en)	2006-04-26	2008-02-01	Wyeth Corp	Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2040745B1 (en)	2006-06-28	2012-12-05	Statens Serum Institut	Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
EP2319862A1 (en)	2006-07-07	2011-05-11	Intercell AG	Small Streptococcus pyogenes antigens and their use
WO2008031133A2 (en)	2006-09-15	2008-03-20	Intercell Ag	Borrelia antigens
EP1923069A1 (en)	2006-11-20	2008-05-21	Intercell AG	Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
AR064642A1 (es)	2006-12-22	2009-04-15	Wyeth Corp	Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US8343510B2 (en)	2007-01-12	2013-01-01	Intercell Ag	Protective proteins of S. agalactiae, combinations thereof and methods of using the same
EP2152731A2 (en)	2007-05-02	2010-02-17	Intercell AG	Klebsiella antigens
EP2012122A1 (en)	2007-07-06	2009-01-07	Medigene AG	Mutated parvovirus structural proteins as vaccines
WO2008145400A2 (en)	2007-05-31	2008-12-04	Medigene Ag	Mutated structural protein of a parvovirus
AU2008265218A1 (en)	2007-06-18	2008-12-24	Intercell Ag	Chlamydia antigens
CN101977927A (zh)	2008-03-17	2011-02-16	英特塞尔股份公司	针对肺炎链球菌保护的肽以及与其有关的组合物、方法和用途
RU2010151562A (ru)	2008-06-20	2012-07-27	ВАЙЕТ ЭлЭлСи (US)	Композиции и способы применения orf1358 из бета-гемолитических стрептококковых штаммов
US20130243779A1 (en)	2009-02-05	2013-09-19	Intercell Ag	Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (en)	2009-02-13	2012-01-18	Intercell AG	Nontypable haemophilus influenzae antigens
SA114350400B1 (ar)	2009-06-22	2016-05-26	ويث ال ال سي	تركيبات وطرق لتحضير تركيبات مولدة للمناعة لمقترن بولي سكاريد كبسولي للنمط المصلي 5 و 8 من المكورات العنقودية الذهبية
CN102481352A (zh)	2009-06-22	2012-05-30	惠氏有限责任公司	金黄色葡萄球菌抗原的免疫原性组合物
US8858958B2 (en)	2009-08-27	2014-10-14	Novartis Ag	Adjuvant comprising aluminum, oligonucleotide and polycation
EP2319871A1 (en)	2009-11-05	2011-05-11	Sanofi-aventis	Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
WO2011042548A1 (en)	2009-10-09	2011-04-14	Sanofi-Aventis	Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP2308896A1 (en)	2009-10-09	2011-04-13	Sanofi-aventis	Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
WO2011101465A1 (en)	2010-02-19	2011-08-25	Intercell Ag	Ic31 nanoparticles
WO2012020326A1 (en)	2010-03-18	2012-02-16	Novartis Ag	Adjuvanted vaccines for serogroup b meningococcus
PT3170508T (pt)	2010-06-04	2020-01-16	Wyeth Llc	Formulações de vacinas
RU2580620C2 (ru)	2010-08-23	2016-04-10	ВАЙЕТ ЭлЭлСи	СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
SMT201700124T1 (it)	2010-09-03	2017-05-08	Valneva Austria Gmbh	Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
AR082925A1 (es)	2010-09-08	2013-01-16	Medigene Ag	Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados
WO2012032489A1 (en)	2010-09-10	2012-03-15	Wyeth Llc	Non-lipidated variants of neisseria meningitidis orf2086 antigens
DK2654784T3 (en)	2010-12-22	2017-02-13	Wyeth Llc	STABLE IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENES
EP2714907B1 (en) *	2011-05-26	2016-06-15	Intervet International B.V.	Immunostimulatory oligodeoxynucleotides
CA2834440A1 (en) *	2011-05-26	2012-11-29	Intervet International B.V.	Immunostimulatory oligodeoxynucleotides
ITMI20111182A1 (it)	2011-06-28	2012-12-29	Canio Buonavoglia	Vaccino per coronavirus canino
SA115360586B1 (ar)	2012-03-09	2017-04-12	فايزر انك	تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en)	2012-03-09	2018-01-09	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
ES2933127T3 (es)	2012-12-20	2023-02-01	Pfizer	Procedimiento de glucoconjugación
US9802987B2 (en)	2013-03-08	2017-10-31	Pfizer Inc.	Immunogenic fusion polypeptides
RU2662968C2 (ru)	2013-09-08	2018-07-31	Пфайзер Инк.	Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016130569A1 (en)	2015-02-09	2016-08-18	Mj Biologics, Inc.	A composition comprising pedv antigens and methods for making and using the composition
EP3140315B1 (en)	2014-05-09	2024-07-24	Universiteit Utrecht Holding B.V.	New cath2 derivatives
AU2016221318B2 (en)	2015-02-19	2020-06-25	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
TWI807252B (zh)	2015-05-04	2023-07-01	美商輝瑞股份有限公司	Ｂ型鏈球菌多醣-蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途
US10751402B2 (en)	2016-11-09	2020-08-25	Pfizer Inc.	Immunogenic compositions and uses thereof
US10183070B2 (en)	2017-01-31	2019-01-22	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
JP2021513840A (ja)	2018-02-16	2021-06-03	２エーファーマアーベー	自己免疫疾患の処置のためのパルボウイルス構造タンパク質
EP3527223A1 (en)	2018-02-16	2019-08-21	2A Pharma AB	Mutated parvovirus structural protein
PH12021552736A1 (en)	2019-05-20	2022-07-11	Valneva Se	A subunit vaccine for treatment or prevention of a respiratory tract infection
WO2020240268A1 (en)	2019-05-31	2020-12-03	Universidad De Chile	An immunogenic formulation that induces protection against shiga toxin-producing escherichia coli (stec)
EP4034157A1 (en)	2019-09-27	2022-08-03	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
US12570700B2 (en)	2020-04-17	2026-03-10	Regents Of The University Of Minnesota	SARS-CoV-2 spike receptor binding domain and compositions and methods thereof
CA3192786A1 (en)	2020-08-26	2022-03-03	Pfizer Inc.	Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
US20230372464A1 (en)	2020-10-07	2023-11-23	Valneva Sweden Ab	Cholera vaccine formulation
WO2023083964A1 (en)	2021-11-11	2023-05-19	2A Pharma Ab	Parvovirus structural protein against beta- and gamma-hpv
WO2023232901A1 (en)	2022-06-01	2023-12-07	Valneva Austria Gmbh	Clostridium difficile vaccine
JP2025532724A (ja)	2022-09-29	2025-10-03	ファイザー・インク	Ｒｓｖｆタンパク質三量体を含む免疫原性組成物
WO2026038177A1 (en)	2024-08-16	2026-02-19	Pfizer Inc.	Immunogenic compositions and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3725545A (en)	1971-02-03	1973-04-03	R Maes	Enhancement of antibody production by nucleic acid-polycation complexes
US3906092A (en)	1971-11-26	1975-09-16	Merck & Co Inc	Stimulation of antibody response
CA2016841C (en) *	1989-05-16	1999-09-21	William D. Huse	A method for producing polymers having a preselected activity
ZA908001B (en) *	1989-10-11	1991-08-28	Merrell Dow Pharma	Inosine/guanosine derivatives as immunosuppressive agents
US5514577A (en)	1990-02-26	1996-05-07	Isis Pharmaceuticals, Inc.	Oligonucleotide therapies for modulating the effects of herpes viruses
WO1992011389A1 (en)	1990-12-21	1992-07-09	F. Hoffmann-La Roche Ag	Hla dqbeta dna typing
US5098437A (en) *	1991-02-13	1992-03-24	Pfizer Hospital Products Group, Inc.	Acetabular cup positioning insert
AU2931692A (en)	1991-10-23	1993-05-21	Baylor College Of Medicine	Fingerprinting bacterial strains using repetitive dna sequence amplification
US5646262A (en) *	1994-07-28	1997-07-08	Georgetown University	Antisense oligonucleotides against hepatitis B viral replication
CA2223061C (en) *	1995-06-06	2008-04-22	Jan Vijg	Method of and apparatus for diagnostic dna testing
ZA964446B (en) *	1995-06-06	1996-12-06	Hoffmann La Roche	Oligonucleotides specific for hepatitis c virus
US20020081577A1 (en) *	1995-06-06	2002-06-27	Robert L. Kilkuskie	Oligonucleotides speciific for hepatitis c virus
CA2267648A1 (en) *	1996-10-02	1998-04-09	David Kilpatrick	Detection and identification of non-polio enteroviruses
JP4111403B2 (ja) *	1996-10-11	2008-07-02	ザリージェンツオブザユニバーシティーオブカリフォルニア	免疫刺激ポリヌクレオチド／免疫調節分子複合体
WO1998055495A2 (en)	1997-06-06	1998-12-10	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US5955443A (en) *	1998-03-19	1999-09-21	Isis Pharmaceuticals Inc.	Antisense modulation of PECAM-1
US6001651A (en) *	1998-03-20	1999-12-14	Isis Pharmaceuticals Inc.	Antisense modulation of LFA-3
IL126919A0 (en) *	1998-11-05	1999-09-22	Univ Ben Gurion	Antisense oligomer
EP1090033B2 (en) *	1998-06-24	2007-12-19	Innogenetics N.V.	Particles of hcv envelope proteins: use for vaccination
IL148843A0 (en) *	1999-09-25	2002-09-12	Univ Iowa Res Found	Immunostimulatory nucleic acids
JP2003531915A (ja) *	2000-05-01	2003-10-28	ハイブリドン・インコーポレイテッド	ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節
WO2001093905A1 (en) *	2000-06-08	2001-12-13	Intercell Biomedizinische Forschungs- Und Entwicklungs Ag	Immunostimulatory oligodeoxynucleotides
AT410173B (de) *	2000-06-08	2003-02-25	Cistem Biotechnologies Gmbh	Antigene zusammensetzung
ES2562456T3 (es) *	2003-03-24	2016-03-04	Valneva Austria Gmbh	Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
US7951845B2 (en) *	2006-01-19	2011-05-31	The Regents Of The University Of Michigan	Composition and method of treating hearing loss

2001
- 2001-06-07 WO PCT/EP2001/006433 patent/WO2001093905A1/en not_active Ceased
- 2001-06-07 KR KR20027016711A patent/KR100799788B1/ko not_active Expired - Lifetime
- 2001-06-07 HU HU0301229A patent/HU228264B1/hu unknown
- 2001-06-07 US US10/297,555 patent/US8568742B2/en active Active
- 2001-06-07 AU AU8181201A patent/AU8181201A/xx active Pending
- 2001-06-07 SK SK1815-2002A patent/SK287689B6/sk not_active IP Right Cessation
- 2001-06-07 BR BRPI0111639A patent/BRPI0111639B8/pt not_active IP Right Cessation
- 2001-06-07 CN CNB018107974A patent/CN1309418C/zh not_active Expired - Lifetime
- 2001-06-07 MX MXPA02012010A patent/MXPA02012010A/es active IP Right Grant
- 2001-06-07 CA CA2411575A patent/CA2411575C/en not_active Expired - Lifetime
- 2001-06-07 AT AT01960277T patent/ATE249839T1/de active
- 2001-06-07 ES ES01960277T patent/ES2206424T3/es not_active Expired - Lifetime
- 2001-06-07 TR TR200302015T patent/TR200302015T4/xx unknown
- 2001-06-07 PT PT01960277T patent/PT1296713E/pt unknown
- 2001-06-07 IL IL15295901A patent/IL152959A0/xx active IP Right Grant
- 2001-06-07 EP EP20010960277 patent/EP1296713B1/en not_active Expired - Lifetime
- 2001-06-07 RU RU2003100409A patent/RU2293573C2/ru active
- 2001-06-07 DE DE2001600814 patent/DE60100814T2/de not_active Expired - Lifetime
- 2001-06-07 JP JP2002501476A patent/JP5271471B2/ja not_active Expired - Lifetime
- 2001-06-07 PL PL358982A patent/PL211036B1/pl unknown
- 2001-06-07 AU AU2001281812A patent/AU2001281812B2/en not_active Expired
- 2001-06-07 RU RU2007103151A patent/RU2413520C2/ru active
- 2001-06-07 DK DK01960277T patent/DK1296713T3/da active
- 2001-06-07 SI SI200130047T patent/SI1296713T1/xx unknown
- 2001-06-07 CZ CZ2002-4168A patent/CZ304195B6/cs not_active IP Right Cessation
2002
- 2002-11-18 IS IS6627A patent/IS1993B/is unknown
- 2002-11-20 IL IL152959A patent/IL152959A/en unknown
- 2002-12-04 NO NO20025835A patent/NO329492B1/no not_active IP Right Cessation
2013
- 2013-01-10 JP JP2013002571A patent/JP5908851B2/ja not_active Expired - Lifetime
- 2013-03-06 US US13/786,815 patent/US8945591B2/en not_active Expired - Fee Related
2014
- 2014-12-30 US US14/585,740 patent/US9492537B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2411575A1 (en)	2001-12-13
HUP0301229A3 (en)	2010-01-28
NO20025835D0 (no)	2002-12-04
US20030171321A1 (en)	2003-09-11
KR20030032964A (ko)	2003-04-26
BRPI0111639B8 (pt)	2021-05-25
IS1993B (is)	2005-03-15
SK18152002A3 (sk)	2003-08-05
MXPA02012010A (es)	2005-04-22
NO20025835L (no)	2002-12-04
IL152959A (en)	2008-04-13
PL211036B1 (pl)	2012-04-30
CN1309418C (zh)	2007-04-11
SK287689B6 (sk)	2011-06-06
BR0111639A (pt)	2003-03-25
KR100799788B1 (ko)	2008-01-31
HUP0301229A2 (hu)	2003-08-28
DK1296713T3 (da)	2004-01-26
JP5271471B2 (ja)	2013-08-21
HK1056678A1 (en)	2004-02-27
CZ304195B6 (cs)	2013-12-27
RU2293573C2 (ru)	2007-02-20
JP2003535146A (ja)	2003-11-25
US20150125488A1 (en)	2015-05-07
EP1296713A1 (en)	2003-04-02
AU8181201A (en)	2001-12-17
PT1296713E (pt)	2004-02-27
US20130183339A1 (en)	2013-07-18
CA2411575C (en)	2015-04-07
JP2013121962A (ja)	2013-06-20
BRPI0111639B1 (pt)	2017-04-11
HU228264B1 (en)	2013-02-28
JP5908851B2 (ja)	2016-04-26
ATE249839T1 (de)	2003-10-15
RU2413520C2 (ru)	2011-03-10
US9492537B2 (en)	2016-11-15
NO329492B1 (no)	2010-11-01
RU2007103151A (ru)	2008-08-20
DE60100814T2 (de)	2004-07-01
US8568742B2 (en)	2013-10-29
IL152959A0 (en)	2003-06-24
WO2001093905A1 (en)	2001-12-13
CZ20024168A3 (cs)	2003-09-17
SI1296713T1 (en)	2004-02-29
DE60100814D1 (de)	2003-10-23
CN1434723A (zh)	2003-08-06
US8945591B2 (en)	2015-02-03
PL358982A1 (pl)	2004-08-23
AU2001281812B2 (en)	2005-04-07
TR200302015T4 (tr)	2004-01-21
ES2206424T3 (es)	2004-05-16
EP1296713B1 (en)	2003-09-17

Publication	Publication Date	Title
IS1993B (is)	2005-03-15	Ónæmisörvandi fádeoxýkirni
DE60221004D1 (de)	2007-08-16	Immunostimulierende oligodeoxyribonuklein moleküle
CY1108158T1 (el)	2014-02-12	Ολιγονουκλεοτιδιο ν3'→ρ5' θειoφωσφοραμιδικα: συνθεση αυτων και χρηση
DE69838449D1 (de)	2007-10-31	Aminooxy-modifizierte oligonukleotide
DE69528362D1 (de)	2002-10-31	Oligomere phosphoramidat- und phosphorthioamidatverbindungen
DK1332209T3 (da)	2010-03-29	Samlinger af repeatproteiner indeholdende repeatmoduler
ATE154029T1 (de)	1997-06-15	7-deazapurin modifizierte oligonukleotide
DK0759927T3 (da)	1999-04-06	Pteridinnucleotidanaloger som fluorescerende DNA prober
BR0213802A (pt)	2004-10-19	Copolìmero útil para a preparação de géis de ácidos
BR9813968A (pt)	2000-09-26	Moléculas de ácido nucléico que codificam proteìnas tendo atividade frutosil transferase e processos para produzir inulina de cadeia longa
CO5070674A1 (es)	2001-08-28	Vacunas con un oligonucleotido cpg como adyuvante
BR9908537A (pt)	2000-11-28	Copolìmeros biocompatìveis e utilização dos mesmos
DE60040980D1 (de)	2009-01-15	Chemisch veränderte, lipolytische enzyme
CY1106041T1 (el)	2011-04-06	Καινοφανης συλλεκτινη
DE69920247D1 (de)	2004-10-21	Veränderung der dns methyltransferase durch kombinationstherapie
HUP0203914A2 (en)	2003-03-28	High order nucleic acid based structures
BR0312460A (pt)	2005-04-26	Suporte sólido, processo de preparação, e, uso do mesmo
ATE242261T1 (de)	2003-06-15	Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen
BRPI0415496A (pt)	2006-12-26	microdisposição de oligonucleotìdeo
BR9803899A (pt)	1999-12-14	Processo para produzir polidiorganossiloxano parcialmente bloqueado terminalmente com grupos siletileno substituídos
KR960700262A (ko)	1996-01-19	이합체 블록의 합성 및 그것의 올리고누클레오티드 어셈블리에의 사용 방법(synthesis of dimmer blocks and their use in assembling oligonucleotides)
AU2493100A (en)	2000-07-24	Compositions and methods relating to cyclic compounds that undergo nucleotide base pair-specific interactions with double-stranded nucleic acids
BRPI0207566B8 (pt)	2021-05-25	processo para preparação de (e)-5-(2-bromovinil)-2'-desoxiuridina
DE60216960D1 (de)	2007-02-01	Verfahren zur herstellung von beta-1,3-n-acetylglucosamin-transferase und einer n-acetylglucosamin enthaltenden saccharidzusammensetzung
DE69928543D1 (de)	2005-12-29	Pteridine-nukleotid-analoge